VTYX

Ventyx Biosciences, Inc. (VTYX) | Rumor.io

Ventyx Biosciences

VTYX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)95%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about VTYX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% +0

Mar 4

The merger between $VTYX and Eli Lilly has been approved by shareholders, with the deal expected to be finalized in the first half of 2026.
Following the merger, $VTYX will be delisted from the NASDAQ and become a wholly-owned subsidiary of Eli Lilly.
The company has voluntarily withdrawn from the $QQQ ETF, potentially triggering a sector rotation and significant volume activity in the stock.

Generated by AI

Sentiment

Of the messages about VTYX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	94.87%	94.87% +12.52	90.43% +7.67
Bearish	—	5.13%	5.13% -12.52	9.57% -7.67

Bullish· Jan 8

Ventyx Biosciences, Inc. has a strong potential for growth, with a debt-free balance sheet and $12M cash positioning the company for a strong 2026 outlook.
Lilly's acquisition of Ventyx Biosciences, Inc. could lead to significant increases in the company's value, given their track record of identifying blockbusters like Tirzepatide.
Ventyx Biosciences, Inc. has a low attention biotech stock with quiet accumulation, which could be a telltale sign of increasing volume and potentially higher prices.

Bearish· Jan 7

The asset's $14 cash offer from Lilly may be an omen for the bio industry, and latecomers may be punished.
The company's management has dropped the ball, and there is a desperation that may have led to a bad deal.
The asset is at risk of falling back to single digits if the deal is rejected, and it has no juice left, making it a good time to sell and re-enter.

Generated by AI

Topics

Of the messages about VTYX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	7.44%
Announcements	—	100%	100%	75.94%
Controversies	—	0%	0%	0.47%
Earnings	—	0%	0%	0.37%
Macro	—	0%	0%	6.38%
Technical Analysis	—	0%	0%	9.41%

Analysts· Sep 12

Credit Suisse maintains a $60 price target on Ventyx Biosciences (VTYX) and believes deucravacitinib's clean label sets a favorable precedent for the TYK2i class.
Oppenheimer analyst Jeff Jones maintains an Outperform rating on VTYX and raises the price target to $65, citing the positive momentum of deucravacitinib's launch.
Piper Sandler analyst Yasmeen Rahimi reiterates an Overweight rating on VTYX with a $50 price target, highlighting the potential for a rally in shares due to the clean label from the FDA.

Announcements· Jan 8

Eli Lilly has agreed to acquire Ventyx Biosciences in a $1.2B deal, with Ventyx's shareholders set to receive $14 per share.
The acquisition is expected to strengthen Eli Lilly's immunology and neurology portfolio, adding oral NLRP3 and IBD assets to its pipeline.
Ventyx's lead program, TYK2, was initially the focus of the company's IPO in 2021, but the company has since pivoted to its inflammasome program, which is now being acquired by Eli Lilly.

Technical Analysis· Oct 23

$VTYX has broken through resistance at 7.7, potentially heading towards 9.11.
The stock's momentum is fading if it slips under 5.90, and it needs to get back over 6.50 with volume for the next move towards 7+.
An inverted head and shoulders pattern appears to have formed on the minute chart, with a potential target of around $8.40, and an Elliott Wave is in progress with a target range between $8.80 and $9.70.

Generated by AI

Community

Of the messages about VTYX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	52.7%	57.83%	46.5%
Newcomers	0%	47.3%	42.17%	53.5%

Regulars· Jan 8

Eli Lilly has agreed to acquire Ventyx Biosciences in a $1.2 billion deal, following positive readouts for Parkinson's and CV treatments.
The acquisition is expected to provide Ventyx with the resources to further develop its pipeline and bring its treatments to market.
This deal marks a significant step forward for Ventyx Biosciences, which will now be integrated into Eli Lilly's portfolio of treatments and therapies.

Newcomers· Jan 10

New investors are buying into Ventyx Biosciences, Inc., with one user buying shares at $2.50 and another mentioning a potential price increase around $7.
Users are discussing the ticker symbol $VTYX in the context of the American market and Saudi Arabian stock market, with one user mentioning a company with a similar ticker ($THH) and another referencing a different ticker ($OFAL).
The main focus of the posts is on the performance and potential of Ventyx Biosciences, Inc., with users sharing their experiences and speculating on its future value.

Generated by AI

Also Discussed

Investors talking about VTYX also mention

#	Name	Attention
1	Monte Rosa Therapeutics, Inc.GLUE	0%0
2	Abivax SAABVX	0.01%-0.01
3	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
4	TERN - Terns Pharmaceuticals, Inc.	——
5	Janux Therapeutics, Inc.JANX	0%0
6	ETNB - 89bio, Inc.	——
7	Erasca Inc.ERAS	0%0
8	ImageneBio, Inc.IKNA	0%0
9	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
10	Acumen Pharmaceuticals, Inc.ABOS	0%new